An Experimental Drug’s Bitter End – NYTimes.com

By ANDREW POLLACK

Holly Usrey-Roos will never forget when her son, Parker, then 10, accidentally broke a drinking glass and said, “I’m sorry, Mom. I love you.”

Ms. Usrey-Roos with her son, Parker. The experimental drug he took for years, she said, “opened the lid and let Parker out.”

Now, however, the drug is being taken away.

The situation raises questions about what, if anything, drug companies owe to patients participating in their clinical trials. It also points out the difficulties in developing drugs to treat autism and fragile X syndrome. If the drug worked so well in some patients, why has it not succeeded so far in clinical trials?

Read the article:  An Experimental Drug’s Bitter End – NYTimes.com.

Explore Current Fragile X Research

FRAXA-funded researchers around the world are leading the way towards effective treatments and ultimately a cure.